HUMA on Nasdaq
Humacyte, Inc.
American biological products company, incorporated in Delaware1
In its 2026 annual report the company says: “Humacyte, Inc. is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, and in the first quarter of 2025 commenced the United States commercial launch of our first FDA-approved product. We are pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs and organ systems with the goal of improving the lives of patients and transforming the practice of medicine.”3 It is headquartered in Durham, North Carolina.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Fusion Pharmaceuticals, Aligos Therapeutics, Inc. or Outlook Therapeutics, Inc., or pick any stock.
- TickerHUMA on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersDurham, North Carolina1
- Incorporated inDE2
- Business address2525 East North Carolina Highway 54, Durham, Nc 277132
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
Humacyte, Inc. is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, and in the first quarter of 2025 commenced the United States commercial launch of our first FDA-approved product. We are pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. We believe our regenerative medicine technology has the potential to overcome limitations in existing standards of care and address the lack of significant innovation in products that support tissue repair, reconstruction and replacement. We are leveraging our novel, scalable technology platform to develop proprietary, bioengineered, acellular human tissues for use in the…3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-5306.0%Operating margin4
-2003.6%Net margin4
-1313.4%Return on equity4
11.40×Debt to equity4
-$105.9MFree cash flow4
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 68% of the revenue Humacyte, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Product | $0 | $1.4M |
| Product and Service, Other | $0 | $649.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue12¢$9.7M
- Research and development88¢$69.3M
Out of $2.0M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $2.0M | $0 |
| Cost of goods sold | $9.7M | $0 |
| Research and development | $69.3M | $88.6M |
| General and administrative | $31.2M | $25.8M |
| Total operating expenses | $110.2M | $114.4M |
| Loss from operations | -$108.1M | -$114.4M |
| Interest income | $2.6M | $4.1M |
| Change in fair value of Contingent Earnout Liability | $59.5M | -$33.0M |
| Interest expense | -$11.2M | -$9.3M |
| Change in fair value of derivatives | $38.8M | $3.9M |
| Loss on extinguishment of debt | -$22.3M | $0 |
| Total other expense, net | $67.3M | -$34.3M |
| Net loss and comprehensive loss | -$40.8M | -$148.7M |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -$0.26 | -$1.26 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -$0.26 | -$1.26 |
| Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic (in shares) | 158.2M shares | 118.5M shares |
| Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, diluted (in shares) | 158.2M shares | 118.5M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2025-06-30 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $50.5M | $44.9M | ||
| Inventory, net | $13.6M | $0 | ||
| Accounts receivable | $441.0K | $0 | ||
| Prepaid expenses and other current assets | $3.3M | $2.9M | ||
| Total current assets | $67.8M | $47.9M | ||
| Restricted cash | $209.0K | $50.2M | ||
| Property and equipment, net | $18.5M | $23.1M | ||
| Finance lease right-of-use assets, net | $29.1M | $15.5M | ||
| Other long-term assets | $672.0K | $1.3M | ||
| Total assets | $116.4M | $137.9M | ||
| Accounts payable | $5.4M | $4.5M | ||
| Accrued expenses | $10.5M | $11.4M | ||
| Finance lease obligation, current portion | $2.4M | $2.9M | ||
| Revenue interest liability, current portion | $0 | $885.0K | ||
| Other current liabilities | $0 | $238.0K | ||
| Total current liabilities | $18.4M | $20.0M | ||
| Long-term debt | $35.4M | $0 | ||
| Contingent Earnout Liability | $11.5M | $71.0M | ||
| Revenue interest liability | $0 | $63.4M | ||
| Common stock warrant liabilities | $19.4M | $19.3M | ||
| Finance lease obligation, net of current portion | $27.0M | $13.6M | ||
| Contingent derivative liability | $0 | $2.4M | ||
| Other long-term liabilities | $1.6M | $983.0K | ||
| Total liabilities | $113.3M | $190.5M | ||
| Preferred stock, $0.0001 par value; 20,000,000 shares designated as of December 31, 2025 and 2024, 0 shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.0001 par value; 350,000,000 and 250,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 193,000,611 and 130,027,509 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $20.0K | $13.0K | ||
| Additional paid-in capital | $729.9M | $633.3M | ||
| Accumulated deficit | -$726.8M | -$686.0M | ||
| Total stockholders equity (deficit) | $3.1M | -$52.7M | $13.5M | |
| Total liabilities and stockholders equity (deficit) | $116.4M | $137.9M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares designated (in shares) | 20.0M shares | 20.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 350.0M shares | 350.0M shares | 250.0M shares | |
| Common stock, shares issued (in shares) | 193.0M shares | 130.0M shares | ||
| Common stock, shares outstanding (in shares) | 193.0M shares | 130.0M shares |
| Period ending | 2025-12-31 | 2025-06-30 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $50.5M | $44.9M | ||
| Inventory, net | $13.6M | $0 | ||
| Accounts receivable | $441.0K | $0 | ||
| Prepaid expenses and other current assets | $3.3M | $2.9M | ||
| Total current assets | $67.8M | $47.9M | ||
| Restricted cash | $209.0K | $50.2M | ||
| Property and equipment, net | $18.5M | $23.1M | ||
| Finance lease right-of-use assets, net | $29.1M | $15.5M | ||
| Other long-term assets | $672.0K | $1.3M | ||
| Total assets | $116.4M | $137.9M | ||
| Accounts payable | $5.4M | $4.5M | ||
| Accrued expenses | $10.5M | $11.4M | ||
| Finance lease obligation, current portion | $2.4M | $2.9M | ||
| Revenue interest liability, current portion | $0 | $885.0K | ||
| Other current liabilities | $0 | $238.0K | ||
| Total current liabilities | $18.4M | $20.0M | ||
| Long-term debt | $35.4M | $0 | ||
| Contingent Earnout Liability | $11.5M | $71.0M | ||
| Revenue interest liability | $0 | $63.4M | ||
| Common stock warrant liabilities | $19.4M | $19.3M | ||
| Finance lease obligation, net of current portion | $27.0M | $13.6M | ||
| Contingent derivative liability | $0 | $2.4M | ||
| Other long-term liabilities | $1.6M | $983.0K | ||
| Total liabilities | $113.3M | $190.5M | ||
| Preferred stock, $0.0001 par value; 20,000,000 shares designated as of December 31, 2025 and 2024, 0 shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.0001 par value; 350,000,000 and 250,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 193,000,611 and 130,027,509 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $20.0K | $13.0K | ||
| Additional paid-in capital | $729.9M | $633.3M | ||
| Accumulated deficit | -$726.8M | -$686.0M | ||
| Total stockholders equity (deficit) | $3.1M | -$52.7M | $13.5M | |
| Total liabilities and stockholders equity (deficit) | $116.4M | $137.9M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares designated (in shares) | 20.0M shares | 20.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 350.0M shares | 350.0M shares | 250.0M shares | |
| Common stock, shares issued (in shares) | 193.0M shares | 130.0M shares | ||
| Common stock, shares outstanding (in shares) | 193.0M shares | 130.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Income (Loss) | -$40.8M | -$148.7M |
| Depreciation expense | $5.3M | $5.1M |
| Stock-based compensation expense | $9.8M | $6.1M |
| Change in fair value of Contingent Earnout Liability | -$59.5M | $33.0M |
| Non-cash interest expense | $9.1M | $7.8M |
| Change in fair value of derivatives | -$38.8M | -$3.9M |
| Loss on disposal of property and equipment | $5.0K | $4.0K |
| Loss on extinguishment of debt | $22.3M | $0 |
| Inventory reserve | $8.9M | $0 |
| Amortization expense | $2.0M | $2.1M |
| Non-cash operating lease costs | $44.0K | $53.0K |
| Accounts receivable | -$261.0K | $0 |
| Inventory | -$21.8M | $0 |
| Prepaid expenses and other current assets | -$527.0K | $88.0K |
| Accounts payable | $973.0K | -$2.0M |
| Accrued expenses | -$1.7M | $2.2M |
| Operating lease obligation | -$44.0K | -$53.0K |
| Net cash used in operating activities | -$105.0M | -$98.1M |
| Purchase of property and equipment, net | -$884.0K | -$1.6M |
| Net cash used in investing activities | -$884.0K | -$1.6M |
| Proceeds from the Term Loan Facility | $39.8M | $0 |
| Payments of transaction costs related to the Loan Agreement | -$774.0K | $0 |
| Payments of costs related to public offering | -$340.0K | -$350.0K |
| Payments on revenue interest liability | -$45.0K | $0 |
| Settlement of the Purchase Agreement | -$88.0M | $0 |
| Proceeds from the Purchase Agreement, net of issuance costs | $0 | $20.0M |
| Payments of transaction costs related to the Purchase Agreement | $0 | -$500.0K |
| Proceeds from the exercise of stock options | $61.0K | $1.5M |
| Proceeds from the JDRF Agreement | $175.0K | $240.0K |
| Payments of finance lease principal | -$2.8M | -$2.6M |
| Net cash provided by financing activities | $61.5M | $114.2M |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -$44.4M | $14.5M |
| Unpaid transaction costs related to the Loan Agreement | $446.0K | $0 |
| Increase in right-of-use assets and lease liabilities resulting from lease remeasurement | $15.0M | $0 |
| Accrual of transaction costs associated with public offering | $156.0K | $0 |
| Debt discount from embedded contingent derivative liability | $0 | $1.6M |
| Issuance of commitment shares pursuant to the Common Stock Purchase Agreement | $0 | $708.0K |
No quarter-by-quarter statement was filed.
Corporate structure
Humacyte, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Humacyte, Inc.
- FRESENIUS MEDICAL CARE HOLDINGS INC /NY/ Filed SCHEDULE 13D/A on Humacyte, Inc., latest Aug 18, 2026 (9 filings since Dec 1, 2023)
- BlackRock Filed SCHEDULE 13G/A on Humacyte, Inc., latest Jul 28, 2026 (3 filings since Oct 24, 2024)
- DAVIDSON KEMPNER CAPITAL MANAGEMENT LP Filed SCHEDULE 13G on Humacyte, Inc., latest Jun 22, 2026
- Fresenius Medical Care Filed SCHEDULE 13D/A on Humacyte, Inc., latest Jan 9, 2026 (2 filings since Oct 16, 2025)
- Laura E. Niklason Filed SC 13D/A on Humacyte, Inc., latest Nov 20, 2024 (9 filings since Sep 19, 2022)
- GLAZER CAPITAL, LLC Filed SC 13G/A on Humacyte, Inc., latest Feb 14, 2022
- Parian Global Management LP Filed SC 13G/A on Humacyte, Inc., latest Feb 9, 2022
- Humacyte, Inc. Durham, North Carolina
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Humacyte, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $59.9M4 Dec 31, 2025 | $59.1M4 Dec 31, 2024 | +1.2% |
| Accumulated depreciation | $41.3M4 Dec 31, 2025 | $36.1M4 Dec 31, 2024 | +14.5% |
| Property and equipment, net | $18.5M4 Dec 31, 2025 | $23.1M4 Dec 31, 2024 | −19.6% |
| Finance-lease assets | $29.1M4 Dec 31, 2025 | $15.5M4 Dec 31, 2024 | +88.2% |
| Operating-lease assets (leased space) | $04 Dec 31, 2025 | $600.0K4 Dec 31, 2024 | −100.0% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $50.5M4 Dec 31, 2025 | $44.9M4 Dec 31, 2024 | +12.4% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $13.6M4 Dec 31, 2025 | $04 Dec 31, 2024 | |
| Work in process | $6.5M4 Dec 31, 2025 | $04 Dec 31, 2024 | |
| Finished goods | $10.1M4 Dec 31, 2025 | $04 Dec 31, 2024 |
Properties, in its own words
Our corporate headquarters, manufacturing, and research and development facilities are located in Durham, North Carolina where we lease approximately 83,000 square feet of space. This space includes approximately 55,000 square feet for production and distribution operations including manufacturing, bioprocessing, quality control, mechanical space and inventory. The remainder of the facility consists of offices, laboratories, and common spaces.
Item 2 of the 10-K filed Mar 27, 2026.3
Leadership
Who has led Humacyte, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2025
- Chief executive officerRajiv Shukla Sep 17, 2020 to Sep 23, 202011
- Chief financial officerDale A. Sander Aug 27, 2021 to now12
- Chief financial officerPatrick A. Sturgeon Sep 17, 2020 to Sep 17, 202013
- Chief operating officerHeather Ledbetter Prichard Aug 27, 2021 to Jan 23, 202514
Board members and other officers (22)
- Chief Medical OfficerShamik J. Parikh Apr 5, 2022 to now15
- Chief Medical OfficerKiernan Thomas Deangelis Aug 27, 2021 to Aug 27, 202116
- Chief Regulatory OfficerWilliam Edward Tente Aug 27, 2021 to Aug 27, 202117
- Chief Commercial OfficerWilliam John Scheessele Aug 27, 2021 to now18
- Board memberD. Scott Coward Sep 28, 2026 to now19
- Board memberPaul Brian Kuznik Sep 28, 2026 to now20
- Board memberJohn Philip Bamforth Jun 17, 2024 to now21
- Board memberDiane Seimetz Jun 13, 2022 to now22
- Board memberCharles Bruce Green Sep 19, 2022 to now23
- Board memberBrady W. Dougan Aug 27, 2021 to now24
- Board memberEmery N. Brown Aug 27, 2021 to now25
- Board memberGordon M. Binder Aug 27, 2021 to May 15, 202426
- Board memberKathleen Sebelius Aug 27, 2021 to now27
- Board memberMax N. Wallace Aug 27, 2021 to now28
- Board memberMichael T. Constantino Aug 27, 2021 to now29
- Board memberSusan Richards Windham-Bannister Aug 27, 2021 to now30
- Board memberTodd Pope Aug 27, 2021 to now31
- Board memberBrian Clanton Robertson Sep 17, 2020 to Sep 17, 202032
- Board memberBruce A. Springer Sep 17, 2020 to Sep 17, 202033
- Board memberRajiv Shukla Sep 17, 2020 to Jun 16, 202311
- Board memberTerrance L. Carlson Sep 17, 2020 to Sep 17, 202034
- Board memberYili Kevin Xie Sep 17, 2020 to Sep 17, 202035
Former names
- Alpha Healthcare Acquisition Corp.Aug 4, 2020 to Aug 26, 20212
Timeline
- Sep 28, 20268-K Executive or director change; Regulation FD disclosure36
- Aug 12, 20268-K Results of operations37
- Jul 31, 20268-K Listing notice or transfer38
- Jun 11, 20268-K Entered a material agreement; Regulation FD disclosure39
- Jun 10, 20268-K Other events40
- Jun 9, 20268-K Bylaws or fiscal year changed; Shareholder vote41
- Jun 5, 20268-K Other events42
- May 8, 20268-K Listing notice or transfer43
- Apr 24, 20268-K Entered a material agreement; Regulation FD disclosure44
- Mar 19, 20268-K Results of operations; Other events45
- Mar 19, 20268-K Entered a material agreement; Regulation FD disclosure46
- Dec 16, 20258-K Entered a material agreement47
- Sep 17, 2020New chief executive Rajiv Shukla becomes CEO11
Calendar
Coming up
- Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.14) a share, on Nov 12, 2025.48
When it reported results
- Aug 12, 2026Reported quarterly or annual results37
- Mar 19, 2026Reported quarterly or annual results45
- Nov 12, 2025Reported quarterly or annual results49
- Aug 11, 2025Reported quarterly or annual results50
- May 13, 2025Reported quarterly or annual results51
- Mar 28, 2025Reported quarterly or annual results52
- Nov 8, 2024Reported quarterly or annual results53
- Aug 13, 2024Reported quarterly or annual results54
Drug trials and FDA: coming up
- Jun 2027Phase 3 trial readout expected Phase 3 trial of Acellular Tissue Engineered Vessel (ATEV) in End Stage Renal Disease (ESRD): primary completion expected Jun 2027 (ClinicalTrials.gov NCT05908084).55
Drug trials and FDA: recently
- Sep 19, 2023Phase 2/3 trial completed Phase 2/3 trial of Acellular Tissue Engineered Vessel (ATEV) in Trauma: primary completion Sep 19, 2023, results posted Jul 29, 2026 (ClinicalTrials.gov NCT03005418).56
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar
Filings
399 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 61 major events, 201 insider forms, 26 large holders, 91 other. The latest 20:
- Oct 7, 20264 EDGAR
- Oct 7, 20264 EDGAR
- Sep 28, 20263 EDGAR
- Sep 28, 20268-K EDGAR
- Sep 28, 20263 EDGAR
- Sep 15, 20264 EDGAR
- Aug 25, 202625-NSE EDGAR
- Aug 21, 20264 EDGAR
- Aug 19, 20264 EDGAR
- Aug 18, 2026SCHEDULE 13D/A EDGAR
- Aug 12, 202610-Q EDGAR
- Aug 12, 20268-K EDGAR
- Jul 31, 20268-K EDGAR
- Jul 28, 2026SCHEDULE 13G/A EDGAR
- Jul 13, 2026SCHEDULE 13D/A EDGAR
- Jun 22, 2026SCHEDULE 13G EDGAR
- Jun 15, 2026SCHEDULE 13D/A EDGAR
- Jun 12, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 12, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 12, 20264 OWNERSHIP DOCUMENT EDGAR
The 399 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
119 open-market trades by officers, directors and large owners since October 2021: 38 buys and 81 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Jones Keith AnthonyDirector | Buy | 10,000 | $0.56 | $5.6K | Form 4 |
| Aug 20, 2026 | Jones Keith AnthonyDirector | Buy | 10,000 | $0.69 | $6.9K | Form 4 |
| Aug 17, 2026 | Jones Keith AnthonyDirector | Buy | 30,000 | $0.59 | $17.7K | Form 4 |
| May 19, 2026 | Sebelius KathleenDirector | Buy | 56,818 | $0.88 | $50.0K | Form 4 |
| May 18, 2026 | Parikh Shamik JChief Medical Officer | Sale | 45,887 | $0.90 | $41.3K | Form 4 |
| May 18, 2026 | Sander Dale A.CFO and Chief Corp. Dev. Off | Sale | 45,887 | $0.90 | $41.3K | Form 4 |
| May 18, 2026 | Constantino Michael T.Director | Buy | 11,000 | $0.89 | $9.8K | Form 4 |
| Aug 20, 2025 | Dougan Brady WDirector | Sale | 591,685 | $1.58 | $934.9K | Form 4 |
| Aug 20, 2025 | Niklason Laura EPresident, CEO and Director | Sale | 591,685 | $1.58 | $934.9K | Form 4 |
| Aug 19, 2025 | Dougan Brady WDirector | Sale | 1,100,000 | $1.63 | $1.8M | Form 4 |
| Aug 19, 2025 | Niklason Laura EPresident, CEO and Director | Sale | 1,100,000 | $1.63 | $1.8M | Form 4 |
| Aug 18, 2025 | Dougan Brady WDirector | Sale | 549,360 | $1.83 | $1.0M | Form 4 |
| Aug 18, 2025 | Niklason Laura EPresident, CEO and Director | Sale | 549,360 | $1.83 | $1.0M | Form 4 |
| Apr 14, 2025 | Scheessele William JohnChief Commercial Officer | Buy | 6,493 | $1.54 | $10.0K | Form 4 |
| Apr 10, 2025 | Sander Dale A.CFO and Chief Corp. Dev. Off | Buy | 20,000 | $1.53 | $30.6K | Form 4 |
| Apr 10, 2025 | Parikh Shamik JChief Medical Officer | Buy | 7,500 | $1.55 | $11.6K | Form 4 |
| Apr 8, 2025 | Sebelius KathleenDirector | Buy | 50,000 | $1.32 | $66.0K | Form 4 |
| Apr 8, 2025 | Green Charles BruceDirector | Buy | 6,000 | $1.29 | $7.7K | Form 4 |
| Apr 7, 2025 | Constantino Michael T.Director | Buy | 16,000 | $1.26 | $20.2K | Form 4 |
| Dec 4, 2024 | Constantino Michael T.Director | Buy | 4,600 | $4.39 | $20.2K | Form 4 |
All 119 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- FRESENIUS MEDICAL CARE HOLDINGS INC /NY/SCHEDULE 13D/A, 9 filings Dec 1, 2023 to Aug 18, 202657
- BlackRockSCHEDULE 13G/A, 3 filings Oct 24, 2024 to Jul 28, 202658
- DAVIDSON KEMPNER CAPITAL MANAGEMENT LPSCHEDULE 13G, 1 filing Jun 22, 202659
- Fresenius Medical CareSCHEDULE 13D/A, 2 filings Oct 16, 2025 to Jan 9, 202660
- Laura E. NiklasonSC 13D/A, 9 filings Sep 19, 2022 to Nov 20, 202461
- GLAZER CAPITAL, LLCSC 13G/A, 1 filing Feb 14, 202262
- Parian Global Management LPSC 13G/A, 1 filing Feb 9, 202263
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Laura E. Niklason | 63 | $633.6K | $5.2M64 |
| 2025 | Dale A. Sander | 66 | $546.0K | $2.1M64 |
| 2025 | Shamik J. Parikh | 53 | $519.5K | $2.1M64 |
| 2024 | President and Chief Executive Officer | $612.4K | $905.4K64 | |
| 2024 | Chief Financial OfficerChief Corporate Development Officer and Treasurer | $505.8K | $704.2K64 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| ANTIPODES PARTNERS Ltd | 10,103,647 | $7.9M | 0.1% | +4,379,897 |
| Vanguard Capital Management LLC | 10,107,679 | $7.9M | 0.0% | +2,949,517 |
| Alyeska Investment Group, L.P. | 6,022,925 | $4.7M | 0.0% | New |
| Davidson Kempner Capital Management LP | 5,000,000 | $3.9M | 0.1% | New |
| BlackRock, Inc. | 4,839,929 | $3.8M | 0.0% | −7,477,026 |
| Great Point Partners LLC | 3,750,000 | $2.9M | 0.7% | No change |
| UBS Group AG | 2,843,493 | $2.2M | 0.0% | +61,423 |
| Aqr Capital Management LLC | 2,597,134 | $2.0M | 0.0% | +672,443 |
| Geode Capital Management, LLC | 2,185,225 | $1.7M | 0.0% | −1,472,883 |
| Millennium Management LLC | 1,909,049 | $1.5M | 0.0% | +1,800,895 |
| Susquehanna International Group, Llp | 1,699,243 | $1.3M | 0.0% | +641,195 |
| Citadel Advisors LLC | 1,443,376 | $1.1M | 0.0% | New |
| Charles Schwab Investment Management Inc | 1,353,515 | $1.1M | 0.0% | +62,170 |
| Vanguard Fiduciary Trust Co | 1,181,276 | $921.4K | 0.0% | +170,247 |
| LPL Financial LLC | 1,025,535 | $800.3K | 0.0% | +161,072 |
| Private Advisor Group, LLC | 965,091 | $753.2K | 0.0% | +132,292 |
| State Street Corp | 842,537 | $657.5K | 0.0% | −2,201,392 |
| Hbk Investments L P | 790,000 | $616.5K | 0.0% | New |
| Wealth Effects LLC | 693,920 | $541.5K | 0.1% | +489,420 |
| Lion Point Capital, LP | 650,000 | $507.3K | 2.4% | No change |
| LuminArx Capital Management LP | 650,000 | $507.3K | 0.3% | New |
| Goldman Sachs Group Inc | 586,524 | $457.7K | 0.0% | −90,491 |
| Bank Of America Corp /de/ | 578,592 | $451.3K | 0.0% | +182,479 |
| Vanguard Portfolio Management LLC | 568,521 | $443.4K | 0.0% | −849,304 |
| Woodline Partners LP | 500,582 | $390.7K | 0.0% | −1,502,000 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
12 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| May 3, 2024 | Tommy TubervilleRepublican, Senate | Sale | $1,001 - $15,000 | +141.0% | Report |
| May 3, 2024 | Tommy TubervilleRepublican, Senate | Partial sale | $15,001 - $50,000 | +141.0% | Report |
| Apr 30, 2024 | Tommy TubervilleRepublican, Senate | Partial sale | $50,001 - $100,000 | +142.5% | Report |
| Mar 21, 2024 | Tommy TubervilleRepublican, Senate | Buy | $1,001 - $15,000 | −135.6% | Report |
| Mar 21, 2024 | Tommy TubervilleRepublican, Senate | Buy | $1,001 - $15,000 | −135.6% | Report |
| Mar 21, 2024 | Tommy TubervilleRepublican, Senate | Buy | $15,001 - $50,000 | −135.6% | Report |
| Feb 12, 2024 | Tommy TubervilleRepublican, Senate | Buy | $15,001 - $50,000 | −142.7% | Report |
| Jan 19, 2024 | Tommy TubervilleRepublican, Senate | Partial sale | $1,001 - $15,000 | +143.5% | Report |
| Jul 25, 2023 | Tommy TubervilleRepublican, Senate | Buy | $1,001 - $15,000 | −154.1% | Report |
| Jul 25, 2023 | Tommy TubervilleRepublican, Senate | Buy | $1,001 - $15,000 | −154.1% | Report |
| Jul 25, 2023 | Tommy TubervilleRepublican, Senate | Buy | $1,001 - $15,000 | −154.1% | Report |
| Mar 30, 2022 | Tommy TubervilleRepublican, Senate | Buy | $15,001 - $50,000 | −162.2% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How Humacyte, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARHumacyte, Inc.1
- CIK0001818382
- Employer ID (EIN)85-17637593
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
- Incorporated inDelaware3
- Fiscal year endsDecember 311
- Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address2525 East North Carolina Highway 54, Durham, NC 277131
- Phone919-313-96331
- Shares outstanding277,798,105 as of Aug 10, 202610
- Public float$280.3M as of Jun 30, 20253
- AuditorPricewaterhouseCoopers LLP, Raleigh, North Carolina PCAOB ID 238; no auditor attestation of internal control over financial reporting3
- On EDGAR sinceAug 4, 20201
- Filings504 in all: 4 (204), 8-K (79), 3 (31), 144 (24), 10-Q (18), 424B3 (15), 425 (13), SC 13D/A (12)1
All 37 form types
CORRESP (11), UPLOAD (11), EFFECT (10), SCHEDULE 13D/A (8), 10-K (6), 424B5 (6), DEF 14A (5), SC 13G (5), DEFA14A (4), S-3 (4), S-4/A (4), S-8 (4), 424B7 (3), POS AM (3), S-1/A (3), SC 13D (3), 25-NSE (2), PRE 14A (2), S-1 (2), SC 13G/A (2), SEC STAFF LETTER (2), 10-K/A (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), S-4 (1), SCHEDULE 13G (1), SCHEDULE 13G/A (1)
- Latest filingsAnnual report (10-K) Mar 27, 2026
Quarterly report (10-Q) Aug 12, 2026
Proxy statement (DEF 14A) Apr 28, 2026
Latest 8-K (8-K) Sep 28, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.0001 per share | HUMA | The Nasdaq Stock Market LLC |
| Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 | HUMAW | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Mar 27, 2026 (Section 12(b) of the Exchange Act).3
Risk factors and legal proceedings
The risks Humacyte, Inc. names in Item 1A of its 10-K filed Mar 27, 2026: 73 risks under these headings, as written.3
- Risks Related to the Development of Symvess and Commercialization of Our Product Candidates
- Our near-term prospects are dependent on the success of Symvess, our sole FDA-approved product, and if we are unable to increase sales in the vascular trauma indication and obtain regulatory approval for Symvess in additional indications, our business, operating results and financial condition will be materially harmed.
- Symvess and our product candidates, if approved, may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
- We may be subject to enforcement action, civil liability, regulatory investigation and penalties if we engage in the off-label promotion of Symvess.
- If our clinical trials are delayed, do not produce favorable results, or otherwise fail to demonstrate safety and efficacy to the satisfaction of the FDA or similar regulatory authorities outside the United States, we may incur significant additional costs or experience significant delays in completing, or ultimately be unable to complete, the development, approval, and commercialization of our product candidates. If we experience significant delays or significant additional costs, our business will be materially harmed.
- Our progress in early stage clinical trials may not guarantee success in late stage clinical trials, and our progress in trials for one product candidate or the FDA’s approval of Symvess may not be indicative of progress in trials for another product candidate.
- Interim, “topline,” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
- If SAEs occur at an unacceptable rate or other unacceptable side effects are identified in our ATEVs we may need to delay, abandon or limit development and marketing of our product candidates.
- We may experience delays or difficulties in the enrollment of patients in our clinical trials, which may delay or prevent additional clinical trials and our receipt of necessary marketing approvals.
- Lack of experience by investigators and surgeons with our ATEVs can lead to incorrect implantation or follow-up procedures which could harm the results of our clinical trials and market acceptance of Symvess and our product candidates.
- We may not be successful in our efforts to use our proprietary scientific technology platform to build a pipeline of additional product candidates.
- The sizes of the market opportunities for Symvess or our product candidates have not been established with precision and are estimates that management believes to be reasonable. If these market opportunities are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the relevant patient population, our revenue and ability to achieve profitability might be materially and adversely affected.
The other 61 risks
- We face and will continue to face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than we do, which may adversely affect our ability to successfully market or commercialize Symvess or our product candidates.
- Our distribution agreement with Fresenius Medical Care imposes obligations on us that may restrict our ability to operate our business in ways we believe to be in our long-term best interest.
- If we receive approval for a product candidate that is not subject to our distribution agreement with Fresenius Medical Care, and we are unable to establish our own marketing, sales and distribution capabilities or are unable to enter into agreements with third parties do so, we may not be able to generate product revenue and will have to alter our development and commercialization plans.
- There is uncertainty with respect to third-party coverage and reimbursement of Symvess and our product candidates, if approved. They may also be subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, any of which could harm our business, prospects, operating results and financial condition.
- Product liability lawsuits against us could cause us to incur substantial liabilities that may not be covered by our limited product liability insurance and may limit the development, approval and commercialization of Symvess and any product candidates that we develop in the future.
- Risks Related to Manufacturing Symvess and Our Product Candidates
- The manufacture of Symvess and our product candidates is complex, we have limited experience manufacturing commercial product, and we have in the past and may in the future encounter batch failures and difficulties in production. If we or any third-party supplier encounter such difficulties, our ability to supply Symvess for commercial sale or our product candidates for clinical trials could be delayed or halted entirely.
- Manufacturing facilities are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we fail to comply with the regulations or maintain the approvals.
- Risks Related to Our Reliance on Third Parties
- We rely on third parties to conduct and support our clinical trials, and those third parties may not perform satisfactorily, including by failing to adhere to regulatory requirements or our stated protocols or to meet deadlines for the completion of such trials.
- We rely on third-party suppliers, including sole source suppliers, to provide certain components for Symvess and our product candidates. Any failure by a third-party supplier to supply these components for manufacture may delay or impair our ability to commercialize Symvess and to complete our clinical trials for our product candidates.
- We intend to rely on our strategic, global relationship with Fresenius Medical Care to undertake, or assist with, the development and commercialization of certain of our product candidates if we receive marketing approval from relevant regulatory authorities. Disruption of this arrangement could materially adversely affect our business, prospects, operating results and financial condition.
- Risks Related to Our Financial Position and Need for Additional Funding
- We have concluded that substantial doubt is deemed to exist concerning our ability to continue as a going concern.
- We have incurred significant losses to date and we expect to continue to incur losses for the foreseeable future and may never be profitable.
- Our ability to use our net operating loss and tax credit carryforwards to offset future taxable income may be subject to certain limitations.
- We expect to need to raise additional funding, which may not be available on acceptable terms, or at all, and any failure to obtain capital when needed may force us to delay, limit or terminate our product development or commercialization efforts.
- Pursuant to the terms of the Loan Agreement, we may be limited in our ability to incur future debt.
- We may not successfully execute or achieve the expected benefits of cost-saving measures that we have taken or may take in the future, and our efforts may result in further actions or additional asset impairment charges and adversely affect our business.
- Risks Related to Government Regulation
- Even though we received marketing approval for Symvess, we continue to be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to significant penalties if we fail to comply with applicable regulatory requirements.
- We may not obtain marketing approval from the FDA for any of our product candidates even if we successfully complete our clinical trials, which failure would materially harm our business, prospects, operating results and financial condition.
- Even though we obtained approval for Symvess from the FDA, we may never obtain approval for our ATEVs outside of the United States, where the regulatory process is also complex and subject to significant uncertainty. Failure to do so would limit our market opportunities and adversely affect our business.
- Even if we seek “rolling review” or priority review, the review time for BLAs for our product candidates may be longer and more expensive than for other products because of the novelty and complexity of our product candidates, which would delay our ability to begin commercialization and earn product revenues.
- We may in the future seek orphan drug designation for the use of our ATEVs to treat congenital pediatric heart defects. We may be unable to obtain such designation or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.
- Inadequate funding for the FDA and other government agencies, including from government shut downs, global health concerns or other disruptions to these agencies’ operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
- Designation of our product candidates for expedited programs, such as Fast Track designation, Breakthrough Therapy Designation, or RMAT designation, or accelerated approval by the FDA, or priority designation by the Department of Defense, may not lead to a faster development or regulatory review or approval process, and even if granted, will not increase the likelihood that our product candidates will receive marketing approval.
- Healthcare reform measures could hinder or prevent commercial success of Symvess or our product candidates.
- If we fail to comply with healthcare regulations, we could face substantial penalties and our business, prospects, operating results and financial condition could be adversely affected.
- We sell Symvess using arrangements that sometimes involve the consignment of inventory, which results in additional risk and uncertainty as to the viability of consigned inventory, inventory accounting, and tax consequences.
- Our business and operations, including our development programs, could be materially disrupted in the event of system failures, security breaches, violations of data protection laws or data loss or damage by us or third parties on which we rely, including our CROs or other contractors or consultants.
- If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines and penalties or incur costs that could harm our business.
- Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation and adverse publicity and could negatively affect our operating results and business.
- We or the third parties upon which we depend may be adversely affected by natural disasters, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.
- We are subject to anti-corruption and a variety of other laws governing our international operations. If we fail to comply with these laws, we could be subject to, among other things, civil or criminal penalties, other sanctions and remedial measures, and reputational damage, which could adversely affect our business, prospects, operating results and financial condition.
- Risks Related to Our Intellectual Property
- Our ability to successfully commercialize Symvess or our product candidates, if approved, may be impaired if we are unable to obtain and maintain effective intellectual property rights for our proprietary scientific technology platform, Symvess and our product candidates.
- The patent protection we obtain for Symvess or our product candidates may not be sufficient enough to provide us with any competitive advantage or our owned or licensed patents may be challenged.
- We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming and unsuccessful.
- Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could harm our business, prospects, operating results and financial condition.
- If we fail to comply with our obligations in our intellectual property licenses with third parties, we could lose license rights that are important to our business.
- We may not be successful in obtaining necessary intellectual property rights to product candidates for our development pipeline through acquisitions and in-licenses.
- We may be unable to protect the confidentiality of our trade secrets, particularly in light of our reliance on third parties, which increases the possibility that such trade secrets will be disclosed or misappropriated, thus harming our business and competitive position.
- Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.
- Patent terms may be inadequate to protect our competitive position on Symvess or our product candidates for an adequate amount of time.
- We may not be able to protect our intellectual property rights throughout the world.
- Some of our internal intellectual property and most of our in-licensed intellectual property has been generated under U.S. Government grants and contracts that trigger certain obligations and U.S. Government rights and thus is subject to federal regulations such as “march-in” rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.
- If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our marks of interest and our business may be adversely affected.
- Intellectual property rights do not necessarily address all potential threats.
- Risks Related to Business Matters and Our Ability to Manage Growth
- Our future success depends on our ability to retain our key employees, consultants and advisors and to attract, retain and motivate qualified personnel.
- We expect to increase the size of our workforce in the future, and we may encounter difficulties in managing this growth, which could harm our operations.
- Risks Related to Ownership of Our Securities
- The price of our common stock may be volatile.
- Reports published by analysts, including projections in those reports that differ from our actual results, could adversely affect the price and trading volume of our common stock.
- We may issue additional shares of common stock or other equity securities without stockholder approval, which would dilute your ownership interests and may depress the market price of our common stock.
- Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment.
- The Public Warrants may not be in the money in the future, and they may expire worthless, and the terms of the Public Warrants may be amended in a manner adverse to a holder if holders of at least 50% of the then outstanding Public Warrants approve of such amendment.
- We may redeem your unexpired Public Warrants prior to their exercise at a time that is disadvantageous to you, thereby making your Public Warrants worth less than they would be if you held and exercised them at a later time.
- We have derivative securities that are accounted for as assets and liabilities and the changes in value of such derivative securities could have a material effect on our financial results.
- Our business could be adversely impacted by inflation.
- We are and may continue to be subject to legal and other proceedings that could cause us to incur significant expenses, divert our management’s attention, and materially harm our business, financial condition, and operating results.
- Changes in U.S. government policies under the Trump administration, including increased tariffs and reductions in federal research funding, could adversely affect our business.
- We may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on our financial condition, results of operations and stock price, which could cause you to lose some or all of your investment.
- The obligations associated with being a public company involve significant expenses and will require significant resources and management attention, which may divert from our business operations.
- We are a “smaller reporting company” within the meaning of the rules adopted by the SEC, and if we take advantage of certain exemptions from disclosure requirements available to smaller reporting companies, this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies.
- If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.
- Anti-takeover provisions in our Second Amended and Restated Certificate of Incorporation and under Delaware law could make an acquisition of the Company, which may be beneficial to our stockholders, more difficult, and may prevent attempts by our stockholders to replace or remove our current management.
Legal proceedings
On November 18, 2024, James A. Cutshall filed a putative class action lawsuit, captioned Cutshall v. Humacyte, Inc., et al., No. 1:24-cv-00954 (the “Securities Litigation”), against the Company and certain of the Company’s officers in the United States District Court for the Middle District of North Carolina. The complaint in the Securities Litigation asserts claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons and entities that purchased or otherwise acquired securities of the Company between May 10, 2024 and October 17, 2024, based on allegations that the defendants made or were responsible for false or misleading statements and omissions related to the BLA for the vascular trauma indication and to alleged deficiencies at the Company’s Durham, North Carolina manufacturing facility. The Complaint seeks a variety of relief, including unspecified compensatory damages, attorneys fees and costs. On January 31, 2025, the court appointed co-lead plaintiffs. On May 22, 2025, the co-lead plaintiffs filed the amended complaint in the Securities Litigation. The amended complaint expands the putative class to include persons and entities that purchased or otherwise acquired securities of the Company between August 14, 2023 and March 25, 2025. It alleges that the defendants made or were responsible for false or misleading statements and omissions related to the safety of Symvess, alleged deficiencies at the Company’s Durham, North Carolina manufacturing facility, and the Company’s financial condition and liquidity. On July 25, 2025, defendants moved to dismiss the amended complaint in its entirety and with prejudice. The court has yet to rule on the motion, which remains pending.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARHumacyte, Inc. filings on SEC EDGAR
- 2SEC EDGARHumacyte, Inc. filings on SEC EDGAR
- 3
- 4SEC EDGARHumacyte, Inc. 10-K for fiscal 2025
- 5SEC EDGARHumacyte, Inc. 10-K for fiscal 2020
- 6SEC EDGARHumacyte, Inc. 10-K for fiscal 2021
- 7SEC EDGARHumacyte, Inc. 10-K for fiscal 2022
- 8SEC EDGARHumacyte, Inc. 10-K for fiscal 2023
- 9SEC EDGARHumacyte, Inc. 10-Q for fiscal 2026
- 10SEC EDGARHumacyte, Inc. 10-Q for fiscal 2026
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19SEC EDGARD. Scott Coward, Board member
- 20SEC EDGARPaul Brian Kuznik, Board member
- 21SEC EDGARJohn Philip Bamforth, Board member
- 22SEC EDGARDiane Seimetz, Board member
- 23SEC EDGARCharles Bruce Green, Board member
- 24SEC EDGARBrady W. Dougan, Board member
- 25SEC EDGAREmery N. Brown, Board member
- 26SEC EDGARGordon M. Binder, Board member
- 27SEC EDGARKathleen Sebelius, Board member
- 28SEC EDGARMax N. Wallace, Board member
- 29SEC EDGARMichael T. Constantino, Board member
- 30
- 31SEC EDGARTodd Pope, Board member
- 32
- 33SEC EDGARBruce A. Springer, Board member
- 34SEC EDGARTerrance L. Carlson, Board member
- 35SEC EDGARYili Kevin Xie, Board member
- 36
- 37SEC EDGARResults of operations
- 38SEC EDGARListing notice or transfer
- 39
- 40SEC EDGAROther events
- 41
- 42SEC EDGAROther events
- 43SEC EDGARListing notice or transfer
- 44
- 45SEC EDGARResults of operations; Other events
- 46
- 47SEC EDGAREntered a material agreement
- 48NasdaqNasdaq calendar
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64